Antibody–Drug Conjugate to Treat Meningiomas

Antibody–Drug Conjugate to Treat Meningiomas

Meningiomas are primary tumors of the central nervous system with high recurrence. It has been reported that somatostatin receptor 2 (SSTR2) is highly expressed in most meningiomas, but there is no effective targeted therapy approved to control meningiomas. This study aimed to develop and evaluate a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Pharmaceuticals (Basel, Switzerland) Switzerland), 2021-05, Vol.14 (5), p.427
Hauptverfasser: Chen, Kai, Si, Yingnan, Ou, Jianfa, Guan, Jia-Shiung, Kim, Seulhee, Ernst, Patrick, Zhang, Ya, Zhou, Lufang, Han, Xiaosi, Liu, Xiaoguang (Margaret)
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies
antibody–drug conjugate
Brain cancer
Cancer therapies
Cell growth
Cytotoxicity
Drug dosages
FDA approval
Lymphoma
meningiomas
monoclonal antibody
Pharmacokinetics
somatostatin receptor 2
targeted therapy
Tumors
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Meningiomas are primary tumors of the central nervous system with high recurrence. It has been reported that somatostatin receptor 2 (SSTR2) is highly expressed in most meningiomas, but there is no effective targeted therapy approved to control meningiomas. This study aimed to develop and evaluate an anti-SSTR2 antibody–drug conjugate (ADC) to target and treat meningiomas. The meningioma targeting, circulation stability, toxicity, and anti-tumor efficacy of SSTR2 ADC were evaluated using cell lines and/or an intracranial xenograft mouse model. The flow cytometry analysis showed that the anti-SSTR2 mAb had a high binding rate of >98% to meningioma CH157-MN cells but a low binding rate of
ISSN:1424-8247
1424-8247
DOI:10.3390/ph14050427